Which has preferable earnings & valuation, EWTX or REPL?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Replimune Group N/A N/A -$313.94M -$3.15 N/A

Is EWTX or REPL more profitable?

Edgewise Therapeutics' return on equity of -39.01% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Replimune Group N/A -159.32% -90.84%

Does the media favor EWTX or REPL?

In the previous week, Replimune Group had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for Replimune Group and 8 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.52 beat Replimune Group's score of 0.28 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 2 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TNGX or REPL more profitable?

Tango Therapeutics' return on equity of -25.75% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Tango Therapeutics N/A -25.75% -23.36% Replimune Group N/A -159.32% -90.84%

Does the media favor TNGX or REPL?

In the previous week, Replimune Group had 10 more articles in the media than Tango Therapeutics. MarketBeat recorded 13 mentions for Replimune Group and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat Replimune Group's score of 0.28 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 2 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, REPL or VKTX?

Viking Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.15 N/A Viking Therapeutics N/A N/A -$359.64M -$4.66 N/A

Is REPL or VKTX more profitable?

Viking Therapeutics' return on equity of -94.56% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -159.32% -90.84% Viking Therapeutics N/A -94.56% -82.75%

Does the media prefer REPL or VKTX?

In the previous week, Viking Therapeutics had 8 more articles in the media than Replimune Group. MarketBeat recorded 21 mentions for Viking Therapeutics and 13 mentions for Replimune Group. Viking Therapeutics' average media sentiment score of 0.60 beat Replimune Group's score of 0.28 indicating that Viking Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 2 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Viking Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ABCL or REPL?

In the previous week, AbCellera Biologics had 4 more articles in the media than Replimune Group. MarketBeat recorded 17 mentions for AbCellera Biologics and 13 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.28 beat AbCellera Biologics' score of 0.07 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 1 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 2 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is REPL or RLAY more profitable?

Relay Therapeutics' return on equity of -42.27% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -159.32% -90.84% Relay Therapeutics N/A -42.27% -38.67%

Does the media refer more to REPL or RLAY?

In the previous week, Replimune Group had 11 more articles in the media than Relay Therapeutics. MarketBeat recorded 13 mentions for Replimune Group and 2 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.51 beat Replimune Group's score of 0.28 indicating that Relay Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 2 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relay Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Replimune Group (REPL) Competitors

$13.07 -0.38 (-2.83%)

Closing price 04:00 PM Eastern

Extended Trading

$13.14 +0.07 (+0.57%)

As of 07:54 PM Eastern

Compare

REPL vs. EWTX, TNGX, VKTX, ABCL, and RLAY

Should you buy Replimune Group stock or one of its competitors? Replimune Group's main competitors and comparable companies include Edgewise Therapeutics (EWTX), Tango Therapeutics (TNGX), Viking Therapeutics (VKTX), AbCellera Biologics (ABCL), and Relay Therapeutics (RLAY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Replimune Group compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

92.5% of Replimune Group shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Edgewise Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Edgewise Therapeutics currently has a consensus target price of $51.33, indicating a potential upside of 25.02%. Replimune Group has a consensus target price of $12.00, indicating a potential downside of 7.51%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Edgewise Therapeutics' return on equity of -39.01% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Replimune Group	N/A	-159.32%	-90.84%

In the previous week, Replimune Group had 5 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for Replimune Group and 8 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.52 beat Replimune Group's score of 0.28 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Summary

Edgewise Therapeutics beats Replimune Group on 9 of the 13 factors compared between the two stocks.

How does Replimune Group compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 5.4% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tango Therapeutics currently has a consensus price target of $43.46, suggesting a potential upside of 82.15%. Replimune Group has a consensus price target of $12.00, suggesting a potential downside of 7.51%. Given Tango Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Tango Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Tango Therapeutics' return on equity of -25.75% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Replimune Group	N/A	-159.32%	-90.84%

Tango Therapeutics has higher revenue and earnings than Replimune Group. Tango Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	64.49	-$101.59M	-$0.85	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

In the previous week, Replimune Group had 10 more articles in the media than Tango Therapeutics. MarketBeat recorded 13 mentions for Replimune Group and 3 mentions for Tango Therapeutics. Tango Therapeutics' average media sentiment score of 0.59 beat Replimune Group's score of 0.28 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tango Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

Summary

Tango Therapeutics beats Replimune Group on 11 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Viking Therapeutics?

Replimune Group (NASDAQ:REPL) and Viking Therapeutics (NASDAQ:VKTX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Viking Therapeutics' return on equity of -94.56% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
Viking Therapeutics	N/A	-94.56%	-82.75%

Replimune Group has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 5.4% of Replimune Group shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Viking Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A

Replimune Group currently has a consensus target price of $12.00, suggesting a potential downside of 7.51%. Viking Therapeutics has a consensus target price of $99.67, suggesting a potential upside of 230.54%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Viking Therapeutics had 8 more articles in the media than Replimune Group. MarketBeat recorded 21 mentions for Viking Therapeutics and 13 mentions for Replimune Group. Viking Therapeutics' average media sentiment score of 0.60 beat Replimune Group's score of 0.28 indicating that Viking Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viking Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Viking Therapeutics beats Replimune Group on 7 of the 13 factors compared between the two stocks.

How does Replimune Group compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

AbCellera Biologics presently has a consensus target price of $13.38, indicating a potential downside of 3.79%. Replimune Group has a consensus target price of $12.00, indicating a potential downside of 7.51%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, equities research analysts clearly believe AbCellera Biologics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

AbCellera Biologics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by insiders. Comparatively, 5.4% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Replimune Group has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
Replimune Group	N/A	-159.32%	-90.84%

In the previous week, AbCellera Biologics had 4 more articles in the media than Replimune Group. MarketBeat recorded 17 mentions for AbCellera Biologics and 13 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.28 beat AbCellera Biologics' score of 0.07 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	1 Very Positive mention(s)	2 Positive mention(s)	11 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Replimune Group	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AbCellera Biologics has higher revenue and earnings than Replimune Group. AbCellera Biologics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	56.73	-$146.41M	-$0.54	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

Summary

AbCellera Biologics beats Replimune Group on 10 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Relay Therapeutics?

Replimune Group (NASDAQ:REPL) and Relay Therapeutics (NASDAQ:RLAY) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Replimune Group has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

In the previous week, Replimune Group had 11 more articles in the media than Relay Therapeutics. MarketBeat recorded 13 mentions for Replimune Group and 2 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.51 beat Replimune Group's score of 0.28 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	2 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relay Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Replimune Group currently has a consensus price target of $12.00, suggesting a potential downside of 7.51%. Relay Therapeutics has a consensus price target of $25.92, suggesting a potential upside of 37.31%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 5.4% of Replimune Group shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Relay Therapeutics' return on equity of -42.27% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
Relay Therapeutics	N/A	-42.27%	-38.67%

Relay Therapeutics has higher revenue and earnings than Replimune Group. Relay Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
Relay Therapeutics	$15.35M	269.46	-$276.48M	-$1.57	N/A

Summary

Relay Therapeutics beats Replimune Group on 12 of the 15 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REPL vs. The Competition

Export

Metric	Replimune Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.23B	$3.83B	$7.09B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.89%
P/E Ratio	-4.15	12.99	274.61	26.05
Price / Sales	N/A	1,288.54	600.51	90.03
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	6.50	16.63	10.92	6.31
Net Income	-$313.94M	-$22.67M	$3.50B	$361.43M
7 Day Performance	5.74%	-3.05%	-2.11%	-1.67%
1 Month Performance	-18.21%	-10.75%	-6.34%	-3.94%
1 Year Performance	181.08%	21.11%	8.81%	2.77%

Replimune Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REPL Replimune Group	1.4504 of 5 stars	$13.07 -2.8%	$12.00 -8.2%	+219.5%	$1.26B	N/A	N/A	465
EWTX Edgewise Therapeutics	2.8514 of 5 stars	$40.02 -2.8%	$51.33 +28.3%	+162.2%	$4.33B	N/A	N/A	127
TNGX Tango Therapeutics	2.3859 of 5 stars	$25.10 +1.9%	$43.46 +73.2%	+206.8%	$4.23B	$62.38M	N/A	137	Gap Up
VKTX Viking Therapeutics	3.2488 of 5 stars	$35.40 -3.7%	$99.67 +181.6%	+11.5%	$4.14B	N/A	N/A	65	Gap Up High Trading Volume
ABCL AbCellera Biologics	1.2316 of 5 stars	$12.86 +1.7%	$12.86 0.0%	+133.4%	$3.93B	$75.13M	N/A	562	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REPL) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Replimune Group (REPL) Competitors

REPL vs. EWTX, TNGX, VKTX, ABCL, and RLAY

How does Replimune Group compare to Edgewise Therapeutics?

Summary

How does Replimune Group compare to Tango Therapeutics?

Summary

How does Replimune Group compare to Viking Therapeutics?

Summary

How does Replimune Group compare to AbCellera Biologics?

Summary

How does Replimune Group compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Replimune Group (REPL) Competitors

REPL vs. EWTX, TNGX, VKTX, ABCL, and RLAY

How does Replimune Group compare to Edgewise Therapeutics?

Do insiders and institutionals believe in EWTX or REPL?

Which has more volatility & risk, EWTX or REPL?

Do analysts recommend EWTX or REPL?

Is EWTX or REPL more profitable?

Does the media favor EWTX or REPL?

Which has preferable earnings & valuation, EWTX or REPL?

Summary

How does Replimune Group compare to Tango Therapeutics?

Do insiders and institutionals hold more shares of TNGX or REPL?

Do analysts rate TNGX or REPL?

Is TNGX or REPL more profitable?

Which has better valuation & earnings, TNGX or REPL?

Does the media favor TNGX or REPL?

Which has more risk and volatility, TNGX or REPL?

Summary

How does Replimune Group compare to Viking Therapeutics?

Is REPL or VKTX more profitable?

Which has more volatility and risk, REPL or VKTX?

Do institutionals and insiders hold more shares of REPL or VKTX?

Which has better earnings and valuation, REPL or VKTX?

Do analysts recommend REPL or VKTX?

Does the media prefer REPL or VKTX?

Summary

How does Replimune Group compare to AbCellera Biologics?

Do analysts prefer ABCL or REPL?

Which has more volatility & risk, ABCL or REPL?

Do institutionals and insiders have more ownership in ABCL or REPL?

Is ABCL or REPL more profitable?

Does the media refer more to ABCL or REPL?

Which has higher valuation & earnings, ABCL or REPL?

Summary

How does Replimune Group compare to Relay Therapeutics?

Which has more volatility & risk, REPL or RLAY?

Does the media refer more to REPL or RLAY?

Do analysts rate REPL or RLAY?

Do insiders and institutionals believe in REPL or RLAY?

Is REPL or RLAY more profitable?

Which has preferable valuation & earnings, REPL or RLAY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools